Avalon Globocare CORP

Change Agents Corporation filed an amendment to its Form 8-K, correcting a prior error and detailing a $280,000 debt issuance with accompanying warrants, alongside an amendment to its equity purchase agreement.

Change Agents Corporation announced the issuance of $280,000 in Original Issue Discount Notes and accompanying pre-funded warrants to accredited investors, alongside amendments to an equity purchase agreement.

Change Agents Corporation announced the successful completion of Phase 2 development for its Catch-Up agentic AI video studio platform, with beta testing set to begin in September 2026.

Change Agents Corporation has amended its equity purchase agreement with Hudson Global Ventures, LLC, adjusting terms for future share purchases.

Change Agents Corporation announced the issuance of $616,000 in original issue discount promissory notes to accredited investors, alongside pre-funded warrants, to repay existing debt and fund working capital.

Change Agents Corporation announced the issuance of 1,550,000 shares of common stock under unregistered equity sales related to consulting agreements.

Change Agents Corporation (CHGA) filed its quarterly report for the period ended June 30, 2026, detailing a significant reduction in net loss but highlighting ongoing financial challenges and a substantial doubt about its ability to continue as a going concern.

Avalon GloboCare Corp. filed its Q1 2026 Form 10-Q, detailing a net loss of $4.48 million and highlighting strategic shifts towards AI-driven content technology and the KetoAir breathalyzer.

Avalon GloboCare Corp. reported a significant increase in net loss for the nine months ended September 30, 2025, alongside a going concern warning and a CEO resignation.

Avalon GloboCare Corp. reported a substantial increase in net loss for Q2 and H1 2025, alongside a significant working capital deficit, raising substantial doubt about its ability to continue as a going concern.

Avalon GloboCare's Q1 2025 shows increased revenue from real property rentals but a larger net loss, raising concerns about the company's ability to continue as a going concern.

Avalon GloboCare Corp. saw a rise in rental income but experienced ongoing net losses in the third quarter of 2024, according to its latest financial report.

Avalon GloboCare Corp. files its annual report on Form 10-K, detailing its financial performance, strategic shifts towards precision diagnostic consumer products, and a pending merger with YOOV Group Holding Limited.

Avalon GloboCare Corp.'s annual 10-K filing details a strategic pivot towards precision diagnostics and clinical laboratory services, alongside updates on financial performance and risk factors.

Michael Mathews, a Director of Avalon GloboCare Corp., reported multiple transactions in common stock on August 5, 2026.

Wenzhao Lu, a Director of Avalon GloboCare Corp., received 200,000 shares of common stock on June 29, 2026.

Steven Andrew Sanders, a Director of Avalon GloboCare Corp., received 200,000 shares of common stock on June 29, 2026.

Michael Mathews, a Director of Avalon GloboCare Corp., received 100,000 shares of common stock on June 29, 2026.

Meng Li, Interim CEO of Avalon GloboCare Corp., received 400,000 shares of common stock on June 29, 2026.

Luisa Ingargiola, Chief Strategy Officer of Avalon GloboCare Corp., received 400,000 shares of common stock on June 29, 2026.

Change Agents Corporation has called a special meeting of stockholders to vote on seventeen proposals, primarily focused on approving various issuances of the company's common stock and amendments to its charter.

Avalon GloboCare Corp. schedules its 2026 Annual Meeting to vote on a reverse stock split, a new equity incentive plan, and the ratification of prior warrant issuances.

Avalon GloboCare Corp. calls a special meeting to approve multiple equity issuances and a reverse stock split to maintain Nasdaq listing and manage its capital structure.

Avalon GloboCare Corp. announced its 2025 Annual Meeting of Stockholders to be held virtually on December 30, 2025, alongside the resignation of CEO Dr. David Jin and the appointment of Meng Li as interim CEO.

Avalon GloboCare Corp. is convening its 2024 Annual Meeting of Stockholders to vote on key proposals including a reverse stock split, share issuance, director elections, and auditor ratification.

Change Agents Corporation has filed an amendment to its S-1 registration statement to permit the resale of up to 5,375,797 shares of its common stock by selling stockholders.

Change Agents Corporation is registering for resale by selling stockholders up to 5,360,797 shares of its common stock, detailing ongoing financial challenges and strategic shifts.

Change Agents Corporation (CHGA) has filed a registration statement for the resale of up to 35,569,258 shares of common stock by selling stockholders.

Avalon GloboCare Corp. has filed a registration statement for the resale of up to 19,436,278 shares of its common stock by selling stockholders.

Armistice Capital, LLC, through its Master Fund, has acquired a 9.99% stake in Change Agents Corporation, signaling a notable investment by the asset manager.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has filed a Schedule 13G, reporting beneficial ownership of 632,752 shares of Change Agents Corporation's common stock, representing 4.99% of the outstanding shares.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.99% of Avalon Globocare Corp.'s common stock as of March 31, 2026.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 7.0% passive beneficial ownership stake in Avalon GloboCare Corp.